medwireNews: Study findings suggest that patients may achieve a sustained reduction in monthly migraine days (MMD) by switching to fremanezumab from another calcitonin gene-related peptide (CGRP) pathway monoclonal antibody (mAb).
15-07-2024 | Migraine | News